Daclatasvir and Sofosbuvir are direct-acting antiviral medicines that have been used together for the treatment of chronic hepatitis C virus (HCV) infection. Understanding Daclatasvir Sofosbuvir drug interactions is important because other prescription medicines, over-the-counter products, and supplements may affect treatment or require additional monitoring.
The combination of Daclatasvir 60 mg and Sofosbuvir 400 mg has been studied, and available interaction data indicate that no dose adjustment is required when these two medicines are used together.
How Do Daclatasvir and Sofosbuvir Work?
Daclatasvir targets the HCV NS5A protein, while sofosbuvir is a nucleotide analogue inhibitor that targets the HCV NS5B polymerase. Their different mechanisms allow them to be used together as part of certain HCV treatment regimens.
However, the appropriate treatment regimen depends on individual factors such as HCV genotype, liver disease status, previous treatment, and other medicines being taken.
Important Daclatasvir Sofosbuvir Drug Interactions
Some medicines can significantly affect daclatasvir exposure. Strong enzyme-inducing medicines, including carbamazepine, can reduce daclatasvir concentrations and may decrease antiviral effectiveness. Liverpool HEP Interactions identifies coadministration of daclatasvir with carbamazepine as contraindicated.
Patients should also tell their healthcare professional about medicines used for:
- Epilepsy and seizures
- Heart and blood-pressure conditions
- Diabetes
- Blood clot prevention
- Acid reflux or stomach problems
- HIV or other infections
- Other liver conditions
For example, interaction information indicates that warfarin may not require a direct dose adjustment with daclatasvir or sofosbuvir, but INR monitoring may be important because changes in liver function during successful HCV treatment can affect anticoagulation control.
Other Medicines and Supplements
Patients should provide a complete list of prescription medicines, non-prescription medicines, vitamins, herbal products, and supplements before starting antiviral therapy.
Importantly, the absence of a medicine from an interaction database does not automatically mean that it is safe to combine with Daclatasvir and Sofosbuvir. Liverpool HEP Interactions specifically notes this limitation in its HCV interaction resources.
Do not start, stop, or change another medicine during HCV treatment without discussing it with a doctor or pharmacist.
What About Other Hepatitis C Medicines?
Daclatasvir should not simply be added to another complete HCV regimen without professional assessment. For example, Liverpool HEP Interactions advises against combining daclatasvir with sofosbuvir/velpatasvir because sofosbuvir/velpatasvir is already a complete regimen containing an NS5A inhibitor.
Similarly, medicines containing sofosbuvir should not automatically be combined with another sofosbuvir-containing product.
Key Takeaway
Checking Daclatasvir Sofosbuvir drug interactions before treatment is an important part of safe HCV therapy. Although daclatasvir 60 mg and sofosbuvir 400 mg have been studied together without requiring dose adjustment, other medicines can change drug exposure or require monitoring.
Patients should provide their healthcare professional with a complete medication list before starting treatment. Healthcare professionals can use current interaction resources and prescribing information to assess individual combinations.
This information is for educational purposes and does not replace advice from a qualified healthcare professional.